Clozapine use in HIV-infected schizophrenia patients: A case-based discussion and review

Psychosomatics

Volumn 50, Issue 6, 2009, Pages 626-632

  Nejad, Shamim Hashemi ^a   Gandhi, Rajesh T ^a   Freudenreich, Oliver ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTILIPEMIC AGENT; ATAZANAVIR; CIDOFOVIR; CIPROFLOXACIN; CLARITHROMYCIN; CLOZAPINE; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ERYTHROMYCIN; FLUCONAZOLE; FOSAMPRENAVIR; FOSCARNET; GANCICLOVIR; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; MICONAZOLE; NAFCILLIN; NELFINAVIR; NEVIRAPINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; AGRANULOCYTOSIS; ALCOHOL CONSUMPTION; ANEMIA; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DRUG ABUSE; DYSLIPIDEMIA; FEMALE; GRANULOCYTOPENIA; HERPES SIMPLEX; HIV ASSOCIATED LIPODYSTROPHY; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LEUKOPENIA; LYMPHOCYTOPENIA; MENTAL HEALTH; MONOTHERAPY; NEGLECT; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PSYCHOSIS; SCHIZOPHRENIA; THROMBOCYTOPENIA; TREATMENT REFUSAL; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

EID: 73349125764     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.50.6.626     Document Type: Article

References (51)

1. World Health Organization: http://www.who.int/whr/2001/en/index.html. Geneva, Switzerland, World Health Organization, 2001
2. Fleishman M: Economic grand rounds: psychopharmacosocioeconomics and the global burden of disease. Psychiatr Serv 2003; 54:142-144
3. Regier DA, Narrow WE, Rae DS, et al: The de facto U.S. mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-94
4. Rosenberg SD, Goodman LA, Osher FC, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31-37
5. Walkup J, Crystal S, Sambamoorthi U: Schizophrenia and major affective disorders among Medicaid recipients with HIV/AIDS in New Jersey. Am J Public Health 1999; 89:1101-1103
6. Wang PS, Bohn RL, Knight E, et al: Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002; 17:504-511
7. Ruo B, Rumsfeld JS, Hlatky MA, et al: Depressive symptoms and health-related quality of life: The Heart and SOULD Study. JAMA 2003; 290:215-221
8. Sambamoorthi U, Walkup J, Olfson M, et al: Antidepressant treatment and health services utilization among HIV-infected Medicaid patients diagnosed with depression. J Gen Intern Med 2000; 15:311-320
9. Paterson DL, Swindells S, Mohr J, et al: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30
10. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50:898-911
11. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
12. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-610
13. Kelly JA, Murphy DA, Bahr GR, et al: AIDS/HIV risk behavior among the chronic mentally ill. Am J Psychiatry 1992; 149:886-889
14. Factor SA, Brown D, Molho ES, et al: Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44(Pt 1):544-546
15. Hriso E, Kuhn T, Masdeu JC, et al: Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991; 148:1558-1561
16. Lera G, Zirulnik J: Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999; 14:128-131
17. Dettling M, Muller-Orlinghausen B, Britsch P: Clozapine treatment of HIV-associated psychosis: too much bone marrow toxicity? Pharmacopsychiatry 1998; 31:156-157
18. Walkup JT, Sambamoorthi U, Crystal S: Use of newer antiretroviral treatments among HIV-infected Medicaid beneficiaries with serious mental illness. J Clin Psychiatry 2004; 65:1180-1189
19. Wagner GJ, Kanouse DE, Koegel P, et al: Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care 2004; 16:501-506
20. Gray R, Brewin E, Noak J, et al: A review of the literature on HIV infection and schizophrenia: implications for research, policy, and clinical practice. J Psychiatr Ment Health Nurs 2002; 9:405-409
21. Nimgaonkar VL, Ward SE, Agarde H, et al: Fertility in schizophrenia: results from a contemporary U.S. cohort. Acta Psychiatr Scand 1997; 95:364-369
22. McEvoy JP, Hatcher A, Appelbaum PS, et al: Chronic schizophrenic women's attitudes toward sex, pregnancy, birth control, and childrearing. Hosp Community Psychiatry 1983; 34:536-539
23. Cournos F, Guido JR, Coomaraswamy S, et al: Sexual activity and risk of HIV infection among patients with schizophrenia. Am J Psychiatry 1994; 151:228-232
24. Aruffo JF, Coverdale JH, Chacko RC, et al: Knowledge about AIDS among women psychiatric outpatients. Hosp Community Psychiatry 1990; 41:326-328
25. Kalichman SC, Kelly JA, Johnson JR, et al: Factors associated with risk for HIV infection among chronic mentally ill adults. Am J Psychiatry 1994; 151:221-227
26. Himelhoch S, McCarthy JF, Ganoczy D, et al: Understanding associations between serious mental illness and HIV among patients in the VA health system. Psychiatr Serv 2007; 58:1165-1172
27. Branson BM, Handsfield HH, Lampe MA, et al: Revised recommendations for HIV testing of adults, adolescents, and pregnant women in healthcare settings. MMWR Recomm Rep 2006; 55(RR14):1-17
28. Freudenreich O, Gandhi RT, Walsh JP, et al: Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics 2007; 48:405-411
29. Chetty M, Murray M: CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007; 8:307-313
30. Okudaira T, Kotegawa T, Imai H, et al: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007; 47:871-876
31. Jaresko GS: Etiology of neutropenia in HIV-infected patients. Am J Health Syst Pharm 1999; 56(suppl 5):S5-S8
32. Volberding PA, Lagakos SW, Koch MA, et al: Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter: The AIDS Clinical Trials Group of The National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322:941-949
33. Fischl M, Galpin JE, Levine JD, et al: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322:1488-1493
34. Krogstad P, Wiznia A, Luzuriaga K, et al: Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28: 1109-1118
35. Kitchen V, Stewart F, Bragman K, et al: Emerging proteinase inhibitors. Lancet 1995; 345:1512
36. Deeks SG: Practical issues regarding the use of antiretroviral therapy for HIV infection. West J Med 1998; 168:133-139
37. Wagstaff AJ, Bryson HM: Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties, and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48:199-226
38. Fanning MM, Read SE, Benson M, et al: Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr 1990; 3:472-479
39. Lea AP, Bryson HM: Cidofovir. Drugs 1996; 52:225-230
40. Gordin FM, Simon GL, Wofsy CB, et al: Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495-499
41. Kovacs JA, Hiemenz JW, Macher AM, et al: Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663-671
42. Carr A, Swanson C, Penny R, et al: Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167:180-185
43. Feola DJ, Thornton AC, Garvy BA: Effects of antiretroviral therapy on immunity in patients infected with HIV. Curr Pharm Des 2006; 12:1015-1022
44. Carr A, Samaras K, Burton S, et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58
45. Carr A, Samaras K, Thorisdottir A, et al: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-209
46. Mackin P, Watkinson HM, Young AH: Prevalence of obesity, glucose homeostasis disorders, and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 2005; 48:215-221
47. McEvoy JP, Meyer JM, Goff DC, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19 -32
48. Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289
49. Saddichha S, Manjunatha N, Ameen S, et al: Diabetes and schizophrenia: effect of disease or drug? results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008; 117:342-347
50. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62
51. Hadigan C, Corcoran C, Basgoz N, et al: Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284:472-477